期刊
FERTILITY AND STERILITY
卷 109, 期 6, 页码 952-963出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.fertnstert.2018.05.006
关键词
Precision medicine; biomarkers; patient monitoring; genomics
资金
- U.S. National Institutes of Health [UL1TR001442, U24AG051129, U19G023122]
- Allen Institute for Brain Science
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001442] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [U19AG023122, U24AG051129] Funding Source: NIH RePORTER
There is a great deal of hype surrounding the concept of personalized medicine. Personalized medicine is rooted in the belief that since individuals possess nuanced and unique characteristics at the molecular, physiological, environmental exposure, and behavioral levels, they may need to have interventions provided to them for diseases they possess that are tailored to these nuanced and unique characteristics. This belief has been verified to some degree through the application of emerging technologies such as DNA sequencing, proteomics, imaging protocols, and wireless health monitoring devices, which have revealed great inter-individual variation in disease processes. In this review, we consider the motivation for personalized medicine, its historical precedents, the emerging technologies that are enabling it, some recent experiences including successes and setbacks, ways of vetting and deploying personalized medicines, and future directions, including potential ways of treating individuals with fertility and sterility issues. We also consider current limitations of personalized medicine. We ultimately argue that since aspects of personalized medicine are rooted in biological realities, personalized medicine practices in certain contexts are likely to be inevitable, especially as relevant assays and deployment strategies become more efficient and cost-effective. ((C) 2018 by American Society for Reproductive Medicine.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据